When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself.
Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform. Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment. Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution.
Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the mechanism that controls gene expression. By analyzing epigenetic markers, Cardio Diagnostics can reveal hidden risks that standard genetic tests might miss, such as those arising from diet, stress, or exposure to pollutants.
The implications are significant. Many people who appear low-risk based on traditional factors—like cholesterol levels or blood pressure—may still be vulnerable due to epigenetic changes. This means that Cardio Diagnostics’ tests could help identify individuals who would otherwise be overlooked, allowing for earlier interventions. Moreover, because epigenetic changes can sometimes be reversed through lifestyle modifications, the tests not only identify risk but also empower patients to take actionable steps to mitigate it.
This approach aligns with a broader shift in medicine toward personalized care. Instead of relying solely on population-level statistics, physicians can use epigenetic data to tailor recommendations to each patient’s unique biological state. For example, a person with a family history of heart disease might be told they are at high risk, but if their epigenetic profile shows no active markers for inflammation or plaque buildup, their actual risk might be lower than expected. Conversely, someone with no family history could discover they have epigenetic changes that significantly raise their risk.
Cardio Diagnostics’ platform is already being used in clinical settings, and the company continues to expand its research. The technology has the potential to transform how cardiovascular disease is prevented and managed. As the science of epigenetics advances, tests like those from Cardio Diagnostics could become standard tools for assessing heart health, much like cholesterol screenings are today. For now, the company is at the forefront of translating this complex biology into practical, actionable insights for patients and healthcare providers.
For more information on Cardio Diagnostics Holdings, visit the company's newsroom at https://ibn.fm/CDIO. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer.
